

Catalog# BP- 50500

## Epratuzumab Biosimilar (CD22 Monoclonal Antibody)

Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab.

Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

Product Details	
CAS No.	205923-57-5
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Epratuzumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human CD22 protein
Purity	>95%
Molecular Weight	146.58 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 $\mu$ M filtered PBS solution, pH 7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.